EP2154958A4 - Traitement des maladies cardiovasculaires et de la dyslipidémie au moyen d'inhibiteurs de la phospholipase a<sb>2</sb>sécrétoire (spla<sb>2</sb>) et thérapies combinées impliquant des inhibiteurs de la spla<sb>2</sb> - Google Patents

Traitement des maladies cardiovasculaires et de la dyslipidémie au moyen d'inhibiteurs de la phospholipase a<sb>2</sb>sécrétoire (spla<sb>2</sb>) et thérapies combinées impliquant des inhibiteurs de la spla<sb>2</sb>

Info

Publication number
EP2154958A4
EP2154958A4 EP08747605A EP08747605A EP2154958A4 EP 2154958 A4 EP2154958 A4 EP 2154958A4 EP 08747605 A EP08747605 A EP 08747605A EP 08747605 A EP08747605 A EP 08747605A EP 2154958 A4 EP2154958 A4 EP 2154958A4
Authority
EP
European Patent Office
Prior art keywords
spla
inhibitors
secretary
dyslipidemia
phospholipase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08747605A
Other languages
German (de)
English (en)
Other versions
EP2154958A1 (fr
Inventor
Joaquim Trias
Colin Hislop
Paul Truex
Heather Fraser
Debra Odink
Scott Chadwick
Kenneth Gould
Marian Mosior
Patrick Eacho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anthera Pharmaceuticals Inc
Original Assignee
Anthera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthera Pharmaceuticals Inc filed Critical Anthera Pharmaceuticals Inc
Publication of EP2154958A1 publication Critical patent/EP2154958A1/fr
Publication of EP2154958A4 publication Critical patent/EP2154958A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08747605A 2007-05-03 2008-05-02 Traitement des maladies cardiovasculaires et de la dyslipidémie au moyen d'inhibiteurs de la phospholipase a<sb>2</sb>sécrétoire (spla<sb>2</sb>) et thérapies combinées impliquant des inhibiteurs de la spla<sb>2</sb> Withdrawn EP2154958A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91591007P 2007-05-03 2007-05-03
US96959107P 2007-08-31 2007-08-31
US87486907A 2007-10-18 2007-10-18
PCT/US2008/062577 WO2008137803A1 (fr) 2007-05-03 2008-05-02 Traitement des maladies cardiovasculaires et de la dyslipidémie au moyen d'inhibiteurs de la phospholipase a2 sécrétoire (spla2) et thérapies combinées impliquant des inhibiteurs de la spla2

Publications (2)

Publication Number Publication Date
EP2154958A1 EP2154958A1 (fr) 2010-02-24
EP2154958A4 true EP2154958A4 (fr) 2011-05-04

Family

ID=39943969

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08747605A Withdrawn EP2154958A4 (fr) 2007-05-03 2008-05-02 Traitement des maladies cardiovasculaires et de la dyslipidémie au moyen d'inhibiteurs de la phospholipase a<sb>2</sb>sécrétoire (spla<sb>2</sb>) et thérapies combinées impliquant des inhibiteurs de la spla<sb>2</sb>

Country Status (8)

Country Link
EP (1) EP2154958A4 (fr)
JP (1) JP2010526152A (fr)
CN (1) CN101742907A (fr)
AU (1) AU2008247451A1 (fr)
BR (1) BRPI0811486A2 (fr)
CA (1) CA2686157A1 (fr)
EA (1) EA200971020A1 (fr)
WO (1) WO2008137803A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2395837A1 (fr) * 2009-01-08 2011-12-21 Anthera Pharmaceuticals, Inc. Inhibiteur de phospholipase a2 (spla2) sécrétoire, compositions de médicament à base de niacine et méthodes de traitement des maladies cardiovasculaires et de la dyslipidémie
RU2483707C1 (ru) * 2012-05-04 2013-06-10 Лира Талгатовна Гильмутдинова Способ санаторной терапии больных с метаболическим синдромом и артериальной гипертензией с применением сульфидных ванн
CN115040508A (zh) * 2022-07-28 2022-09-13 上海市同仁医院 吲哚-3-乙醛在制备新型抗肥胖活性制剂中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055108A2 (fr) * 2000-01-25 2001-08-02 Eli Lilly And Company Methode de traitement d'inflammations au moyen d'inhibiteurs spla¿2?
WO2002008189A1 (fr) * 2000-07-24 2002-01-31 The University Of Queensland Composes et inhibiteurs de phospholipases
EP1378246A1 (fr) * 2001-03-19 2004-01-07 Shionogi & Co., Ltd. Remedes contre l'arteriosclerose
WO2007056281A2 (fr) * 2005-11-03 2007-05-18 Ilypsa, Inc. Composes d'indole multivalents et leur utilisation en tant qu'inhibiteurs de phospholipases a2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
CN1303290A (zh) * 1998-05-01 2001-07-11 伊莱利利公司 sPLA2抑制剂酯
WO2006034435A2 (fr) * 2004-09-21 2006-03-30 Point Therapeutics, Inc. Methodes et composition permettant de traiter les affections associees au glucose, le syndrome metabolique, les dyslipidemies et d'autres affections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055108A2 (fr) * 2000-01-25 2001-08-02 Eli Lilly And Company Methode de traitement d'inflammations au moyen d'inhibiteurs spla¿2?
WO2002008189A1 (fr) * 2000-07-24 2002-01-31 The University Of Queensland Composes et inhibiteurs de phospholipases
EP1378246A1 (fr) * 2001-03-19 2004-01-07 Shionogi & Co., Ltd. Remedes contre l'arteriosclerose
WO2007056281A2 (fr) * 2005-11-03 2007-05-18 Ilypsa, Inc. Composes d'indole multivalents et leur utilisation en tant qu'inhibiteurs de phospholipases a2

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN W M ET AL: "Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A2", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 522, no. 1-3, 3 July 2002 (2002-07-03), pages 113 - 118, XP004369256, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(02)02907-1 *
MA J ET AL: "Are evidence-based cardiovascular prevention therapies being used? A review of aspirin and statin therapies", PREVENTION AND CONTROL, ELSEVIER, NL, vol. 1, no. 4, 1 December 2005 (2005-12-01), pages 285 - 295, XP025337910, ISSN: 1573-2088, [retrieved on 20051201], DOI: 10.1016/J.PRECON.2006.05.002 *
ROBINSON JENNIFER G ET AL: "Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, EXPERT REVIEWS LTD, GB, vol. 4, no. 4, 1 July 2006 (2006-07-01), pages 461 - 476, XP008134541, ISSN: 1744-8344, DOI: 10.1586/14779072.4.4.461 *
RODONDI NICOLAS ET AL: "Aspirin for the primary prevention of cardiovascular disease a comprehensive review", COMPREHENSIVE THERAPY, vol. 31, no. 3, October 2005 (2005-10-01), pages 186 - 193, XP002629623, ISSN: 0098-8243 *
See also references of WO2008137803A1 *
VERVOORDELDONK M J ET AL: "Aspirin inhibits expression of the interleukin-1beta-inducible group II phospholipase A2.", FEBS LETTERS 11 NOV 1996 LNKD- PUBMED:8941724, vol. 397, no. 1, 11 November 1996 (1996-11-11), pages 108 - 112, XP002629622, ISSN: 0014-5793 *
WIKLUND O ET AL: "Effects of simvastatin and atorvastatin on inflammation markers in plasma", JOURNAL OF INTERNAL MEDICINE, vol. 251, no. 4, April 2002 (2002-04-01), pages 338 - 347, XP002629621, ISSN: 0954-6820 *

Also Published As

Publication number Publication date
BRPI0811486A2 (pt) 2014-09-30
CN101742907A (zh) 2010-06-16
JP2010526152A (ja) 2010-07-29
AU2008247451A1 (en) 2008-11-13
EA200971020A1 (ru) 2010-10-29
WO2008137803A1 (fr) 2008-11-13
CA2686157A1 (fr) 2008-11-13
EP2154958A1 (fr) 2010-02-24

Similar Documents

Publication Publication Date Title
FR24C1008I1 (fr) Anticorps dirigés contre l&#39;inhibiteur de la voie du facteur tissulaire
EP2242768A4 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d&#39;utilisation de ces derniers
EP2373691A4 (fr) Anticorps anti-fxi et procédés d&#39;utilisation
EP2086583A4 (fr) Anticorps anti-vegf entièrement humains et leurs procédés d&#39;utilisation
DK3323815T3 (en) Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
EP2427479A4 (fr) Anticorps et procédés d&#39;utilisation de ceux-ci
EP1793855A4 (fr) Prevention et traitement de maladies synucleinopathique et amyloidogenique
IL196129A0 (en) Human protein tyrosine phosphatase inhibitors and methods of use
ZA200900558B (en) Human protein tyrosine phosphatase inhibitors and methods of use
EP2073811A4 (fr) Inhibiteurs de kinase utiles pour le traitement de maladies myéloproliférantes et d&#39;autres maladies proliférantes
EP2212432A4 (fr) Anticorps anti-vegf entièrement humains et leurs procédés d&#39;utilisation
EP2001510A4 (fr) Procédés de traitement du lupus au moyen d&#39;anticorps cd4
EP2355849A4 (fr) Procédés d&#39;amélioration de l&#39;efficacité thérapeutique et utilisation de fragments d&#39;anticorps
EP1765379A4 (fr) Compositions pharmaceutiques de co-cristal et methodes d&#39;utilisation associees
EP2563381A4 (fr) Découverte innovante de compositions thérapeutiques, de diagnostic et d&#39;anticorps se rapportant à des fragments protéiques d&#39;isoleucyl arnt synthétases
EP2130146A4 (fr) Analyse de l&#39;efficacité du marketing et du divertissement
EP2485751A4 (fr) Procédés de traitement de la dépression et d&#39;autres maladies associées
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l&#39;administration medicamenteuse et des methodes de traitement utilisant celles-ci
EP1973546A4 (fr) Inhibiteurs de proteine de transfert des esters de cholesterol
EP1933873A4 (fr) Procedes et compositions destinees au traitement de patients atteints de maladies positives pour des auto-anticorps
EP2321356A4 (fr) Anticorps monoclonaux contre l&#39; inhibiteur de la voie du facteur tissulaire (tfpi)
EP2627356A4 (fr) Anticorps contre l&#39;oncostatine m humaine et procédés d&#39;utilisation
EP2097105A4 (fr) Anticorps anti-p-selectine et procedes pour les utiliser dans le traitement des maladies inflammatoires
EP2201376A4 (fr) Nouveau biomarqueur pour surveiller le développement de maladies et évaluer l&#39;efficacité de thérapies
EP2048163A4 (fr) Anticorps anti-intégrine alpha-9 humaine et utilisation de celui-ci

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1139282

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20110401

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/10 20060101ALI20110325BHEP

Ipc: A61K 45/06 20060101ALI20110325BHEP

Ipc: A61K 31/404 20060101ALI20110325BHEP

Ipc: A61K 31/19 20060101ALI20110325BHEP

Ipc: A01N 37/10 20060101AFI20081127BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20120829

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1139282

Country of ref document: HK